Veracyte, Inc. (VCYT) News

Veracyte, Inc. (VCYT): $27.56

-1.36 (-4.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VCYT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 453

in industry

Filter VCYT News Items

VCYT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VCYT News Highlights

  • For VCYT, its 30 day story count is now at 6.
  • Over the past 18 days, the trend for VCYT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about VCYT are LUNG and NOVA.

Latest VCYT News From Around the Web

Below are the latest news stories about Veracyte Inc that investors may wish to consider to help them evaluate VCYT as an investment opportunity.

Veracyte' test can help accelerate timely treatment for lung cancer patients: study

Veracyte (VCYT +1.1%) said new data suggests that its Percepta Genomic Sequencing Classifier (GSC) test can accelerate delivery of curative therapy for patients with high-risk lung nodules and inconclusive bronchoscopy results. The company said the findings from the study, which were published in BMC Pulmonary Medicine, also show that the test can...

Seeking Alpha | January 24, 2022

Aegon Asset Management Uk Plc Buys Autodesk Inc, Advanced Drainage Systems Inc, Stanley Black ...

Investment company Aegon Asset Management Uk Plc (Current Portfolio) buys Autodesk Inc, Advanced Drainage Systems Inc, Stanley Black & Decker Inc, McCormick Inc, Workiva Inc, sells Mastercard Inc, Ansys Inc, Bandwidth Inc, The Kroger Co, Kellogg Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Aegon Asset Management Uk Plc.

Yahoo | January 24, 2022

New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer

SOUTH SAN FRANCISCO, Calif., January 24, 2022--Veracyte Announced New Data Demonstrating Percepta Genomic Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer

Yahoo | January 24, 2022

Is Veracyte Inc (VCYT) A Good Stock To Buy?

In this article we will take a look at whether hedge funds think Veracyte Inc (NASDAQ:VCYT) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]

Yahoo | January 12, 2022

Veracyte announces key leadership promotions to advance strategic global vision

Veracyte (VCYT) announces key leadership promotions that further position the company to achieve its strategic global vision.Effective immediately, Tina Nova, Ph.D., is President

Seeking Alpha | January 6, 2022

Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision

SOUTH SAN FRANCISCO, Calif., January 06, 2022--Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision

Yahoo | January 6, 2022

Veracyte (NASDAQ:VCYT) Stock Price Up 3.4%

Veracyte, Inc. (NASDAQ:VCYT) rose 3.4% on Wednesday . The company traded as high as $45.14 and last traded at $44.79. Approximately 6,255 shares were traded during trading, a decline of 99% from the average daily volume of 757,466 shares. The stock had previously closed at $43.30. VCYT has been the subject of a number of []

Dakota Financial News | December 24, 2021

Karin Eastham Sells 5,000 Shares of Veracyte, Inc. (NASDAQ:VCYT) Stock

Veracyte, Inc. (NASDAQ:VCYT) Director Karin Eastham sold 5,000 shares of Veracyte stock in a transaction that occurred on Friday, December 17th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed []

Dakota Financial News | December 22, 2021

Veracyte Inc. (NASDAQ: VCYT) -8.71% Decline Turns Investors Off From Company Stock

Veracyte Inc. (NASDAQ:VCYT) traded at $41.07 at close of the session on Monday, 12/20/21, made a downward move of -8.71% on its previous days price. Looking at the stock we see that its previous close was $44.99 and the beta (5Y monthly) reads 0.77 with the days price range being $40.85 $43.825. In terms Veracyte Inc. (NASDAQ: VCYT) -8.71% Decline Turns Investors Off From Company Stock Read More »

Stocks Register | December 21, 2021

Veracyte, Inc. (NASDAQ:VCYT) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC raised its position in shares of Veracyte, Inc. (NASDAQ:VCYT) by 292.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 957,501 shares of the biotechnology company’s stock after buying an additional 713,726 shares during the quarter. Fisher Asset Management LLC […]

Dakota Financial News | December 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.62 seconds.